Supplementation of Spironolactone drug to diabetes patients taking antihypertensive drugs, reduced the chances of developing kidney failure
Professor Kaspar Rossing and his colleagues from the Steno Diabetes Center, Denmark has found that supplementation of Spironolactone drug to diabetes patients taking antihypertensive drugs, reduced the chances of developing kidney failure and reduced blood pressure and albumin protein in urine of these patients.
Diabetes patients with high blood pressure are more prone to kidney diseases. Supplementation of Spironolactone has found to inhibit aldosterone, as this hormone increase the urinary protein levels leading to kidney dysfunction. Most of the hypertensive drugs may be useful in diabetic patients already having kidney damage, but does not protect these patients prior to occurrence. The study was conducted in 21 diabetic patients with type 2 diabetes, the patients were asked to take spironolactone for 8 weeks and after the treatment, the urinary albumin levels of the study patients dropped by 33 % and also reduced their upper and lower blood pressure. Though one patient developed low potassium levels the patient recovered rapidly. Further research is required regarding the supplementation of spironolactone.[SOURCE: Diabetes Care, September 2005.]
